Instalab
logoInstalab

Dog (Can f 3) IgE

Blood Test
See whether your dog allergy involves the cross-reactive albumin pathway that can also trigger reactions to cats, horses, and other furry animals.
4.9 (4,174 reviews)
Tested by Diagnostic Solutions Lab
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Dog (Can f 3) IgE test?

This test is most useful if any of these apply to you.

Reacting to More Than One Pet
If you sneeze, wheeze, or itch around dogs, cats, and horses, this test can help identify whether a cross-reactive protein is driving symptoms across species.
Living With Asthma and Pet Exposure
If you have asthma and a pet at home, knowing your component profile helps explain symptom severity and guides whether immunotherapy is worth pursuing.
Considering Getting a Dog
If you have known cat or horse allergy and want to bring a dog into your home, this result tells you whether cross-reactive risk is likely to follow.
Standard Allergy Tests Were Unclear
If whole dander testing was negative or equivocal but you still react around animals, component testing can find the specific protein your body targets.

About Dog (Can f 3) IgE

If you have allergy symptoms around dogs but also seem to react to cats, horses, or other furry pets, this test helps explain why. It measures whether your immune system has produced antibodies against a specific dog protein called Can f 3, which is found in the blood of nearly every furry mammal and is shed into the environment through dander, hair, and saliva.

A positive result points to a sensitization pattern that, when combined with reactions to other dog components, has been linked to broader and sometimes more severe allergic disease. It can reshape how you think about exposure, treatment, and even which animals you can safely live with.

What This Test Actually Measures

Can f 3 (the third officially named allergen from Canis familiaris, the domestic dog) is dog serum albumin, a protein that circulates in the dog's bloodstream and also shows up in their hair, dander, and saliva. The test looks for IgE (immunoglobulin E), an antibody your immune system makes when it has decided a harmless protein is a threat. A positive Can f 3 IgE result means your body is primed to react to dog albumin on contact.

Serum albumin is one of the most evolutionarily conserved proteins across mammals, meaning the cat version, horse version, rabbit version, and guinea pig version all look strikingly similar to your immune system. That structural overlap explains why Can f 3 sensitization rarely stays confined to dogs.

Why Can f 3 Has a Distinct Role Among Dog Components

Dog allergy testing has moved beyond the old whole-dander extract. Modern panels split the dog allergen into individual components like Can f 1, 2, 3, 4, 5, and 6. Each tells a different story. Can f 1 and Can f 5 are the most common dog sensitizers and tend to predict classic dog allergy symptoms. Can f 3 is generally less common but carries different information, because it specifically flags the cross-reactive albumin pathway.

Reported rates of Can f 3 sensitization vary widely depending on the population studied. In some selected clinical cohorts of dog-allergic patients, roughly half tested positive for Can f 3, while broader allergy populations often report much lower rates, sometimes only a few percent. Among Korean adults sensitized to dog dander, 26.5% tested positive for Can f 3. In a Swedish adult cohort sensitized to dog, most participants had IgE to at least one dog component, with Can f 3 appearing less frequently than Can f 1 or Can f 5 but still part of the picture.

Cross-Reactivity With Cats, Horses, and Other Mammals

This is where Can f 3 earns its place in a workup. Because mammalian serum albumins share so much structure, an immune system that recognizes Can f 3 often also recognizes Fel d 2 (cat albumin) and Equ c 3 (horse albumin). Studies measuring IgE responses across these albumins found strong cross-correlations, meaning the three antibodies tend to rise and fall together.

Patients who test positive for Can f 3 have notably higher rates of sensitization to extracts from cat, horse, rabbit, mouse, rat, guinea pig, and other furry animals. They also report worse rhinitis symptom scores. It is worth noting, though, that lipocalin proteins (such as Can f 1, Can f 6, Fel d 4, and Equ c 1) are generally the more common drivers of cross-sensitization between species in most populations, while serum albumins like Can f 3 contribute meaningfully but tend to play a secondary role.

Asthma and Respiratory Disease Risk

Sensitization to multiple dog components, especially when Can f 3 is part of the mix, is associated with more severe respiratory disease. In adult studies, people with positive Can f 3 IgE were more likely to have moderate-to-severe rhinitis and a diagnosis of asthma. Higher Can f 3 levels specifically were seen in people who developed rhinoconjunctivitis (itchy, runny nose and eyes) on dog exposure.

The pattern matters more than any single number. Polysensitization, meaning IgE responses to three or more dog components at once, is consistently linked to asthma and more severe disease. In a population study of 19-year-olds in northern Sweden, high-titer IgE to cat and dog allergens was strongly associated with asthma diagnosis, severity, and persistence, even among people who did not currently live with a pet.

Atopic Dermatitis Connections

In a study of 100 atopic dermatitis (eczema) patients tested with a molecular allergy panel, high IgE levels across multiple components, including dog allergens, were associated with more severe skin disease and coexisting asthma or rhinitis. The study examined broad polysensitization patterns rather than isolating Can f 3 specifically, but Can f 3 sits within this wider pattern that tends to mark people whose allergic disease is more aggressive across multiple organ systems.

What a Low or Absent Result Means

A negative or very low Can f 3 IgE does not rule out dog allergy. You can still react strongly to dogs through other components, particularly Can f 1 (a lipocalin protein) or Can f 5 (a prostatic kallikrein expressed in the prostate of male dogs and therefore present at higher levels in dander from male dogs). A negative Can f 3 simply tells you the cross-reactive albumin pathway is not driving your allergy, which is useful information about which animals you are likely safe around.

When Results Can Be Misleading

Several factors can make a single Can f 3 IgE reading harder to interpret than it appears:

  • Recent intense allergen exposure: spending hours around dogs in the days before a draw can transiently shift IgE patterns, though the magnitude of this effect on Can f 3 specifically has not been well quantified.
  • Antihistamines and oral steroids: these medications do not meaningfully change serum IgE levels for blood-based component testing, but they do suppress skin prick test responses, which is why blood testing is often preferred when someone cannot stop their medications.
  • Assay differences between labs: different commercial platforms (such as ImmunoCAP, Immulite, or multiplex chips like ISAC and ALEX) can give modestly different absolute numbers for the same sample. If you retest, use the same lab and platform when possible.
  • Cross-reactive results without clinical relevance: a positive Can f 3 IgE can show up in someone who has no current dog symptoms, especially if they are sensitized to cat or horse albumin. The lab number alone does not predict whether you will have a reaction.

Why One Reading Is Not Always Enough

IgE sensitization patterns can shift over time, especially in childhood and adolescence, and they respond to changes in pet exposure, immunotherapy, and the natural evolution of allergic disease. A single Can f 3 IgE result is a snapshot. The trajectory, when retesting is appropriate, is what tells you whether your immune system is becoming more tolerant, more reactive, or stable.

There is no formal evidence-based guideline for how often to repeat component-resolved IgE testing. In practice, many clinicians repeat testing when something meaningful has changed, such as acquiring or giving up a pet, starting allergen immunotherapy, or a notable shift in symptoms. Tracking the trend across the full dog component panel, not just Can f 3 in isolation, gives you the most useful picture.

Decision Pathway for an Unexpected Result

A positive Can f 3 IgE should prompt a broader workup rather than a single conclusion. The combinations of findings matter more than the absolute number on any one component.

  • Order or review the full dog component panel (Can f 1, 2, 3, 4, 5, 6) to see whether you are monosensitized to albumin or polysensitized. Polysensitization is the stronger signal for severe disease.
  • Add cat and horse component testing (Fel d 1, Fel d 2, Equ c 1, Equ c 3) to map the extent of cross-reactivity, especially if you have exposure to those animals or are considering it.
  • Consider an allergist or immunologist consultation if results show polysensitization, especially alongside asthma or moderate-to-severe rhinitis. Component-resolved profiles influence whether allergen immunotherapy is likely to help.
  • Check standard inflammatory and respiratory markers if symptoms are escalating. Total IgE and a complete blood count with eosinophils provide context about overall atopic load.

What this means for you: a positive Can f 3 result is not a verdict, it is a clue. It tells you that the route your allergy travels includes the cross-reactive albumin pathway, which has implications for every furry pet you might encounter, not just the one in your living room.

Frequently Asked Questions

References

16 studies
  1. Curin M, Swoboda I, Wollmann E, Lupinek C, Spitzauer S, Van Hage M, Valenta RThe Journal of Allergy and Clinical Immunology2014
  2. ÖZuygur Ermis SS, Borres M, Basna R, Ekerljung L, Malmhäll C, Goksör E, Wennergren G, Rådinger M, Lötvall J, Lundbäck B, Kankaanranta H, Nwaru BClinical and Experimental Allergy2022
  3. Hemmer W, Sestak-greinecker G, Braunsteiner T, Wantke F, Wöhrl SAllergy2021